Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sales of chemically synthesized peptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet. The company was founded on April 2, 2003 and is headquartered in Shenzhen, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company